Evogene Establishes Highly Dilutive $2.9M ATM Offering Amidst Delisting Concerns

summarizeSummary

Evogene Ltd. launched a new At-The-Market (ATM) offering to sell up to $2.9 million in shares, representing over 40% of its market cap, as it navigates delisting threats and going concern doubts.

check_boxKey Events · Financing and Capital Events · EVGN

• New ATM Program Established

  Evogene entered into a Sales Agreement with A.G.P./Alliance Global Partners to sell up to $2,926,500 of ordinary shares through an At-The-Market (ATM) offering.

• Significant Potential Dilution

  The maximum offering amount of $2.9 million represents over 40% of the company's current market capitalization, indicating a highly dilutive capital raise if fully utilized.

• Context of Financial Distress

  This capital raise follows recent disclosures of a Nasdaq delisting notice, substantial doubt about the company's ability to continue as a going concern, and a wider net loss in Q1 2026.

• Utilizes Existing Shelf Registration

  The shares will be issued under a shelf registration statement on Form F-3 (File No. 333-277565) that was declared effective on March 28, 2024.

auto_awesomeAnalysis · EVGN · Industrial Applications And Services

Evogene Ltd. has established an At-The-Market (ATM) offering program to sell up to $2.9 million in ordinary shares. This represents over 40% of the company's current market capitalization, indicating a highly dilutive capital raise. The company is currently facing a Nasdaq delisting notice and has previously disclosed substantial doubt about its ability to continue as a going concern, making this capital raise critical for its operational runway but at a significant cost to existing shareholders.